Intra-Cellular Therapies Inc (ITCI)
70.90
-0.19
(-0.27%)
USD |
NASDAQ |
Jun 27, 16:00
70.90
0.00 (0.00%)
After-Hours: 20:00
Intra-Cellular Therapies Revenue (Annual): 462.18M for Dec. 31, 2023
Revenue (Annual) Chart
Historical Revenue (Annual) Data
| Date | Value |
|---|---|
| December 31, 2023 | 462.18M |
| December 31, 2022 | 249.13M |
| December 31, 2021 | 81.71M |
| December 31, 2020 | 22.53M |
| December 31, 2019 | |
| December 31, 2018 |
| Date | Value |
|---|---|
| December 31, 2017 | 0.2458M |
| December 31, 2016 | 0.3307M |
| December 31, 2015 | 0.0307M |
| December 31, 2014 | 0.5475M |
| December 31, 2013 | 2.737M |
| December 31, 2012 | 3.118M |
Revenues Definition
Revenues measure the total amount of value that a company brings in during a certain period. This is also considered the "top-line" of the income statement. Revenues are used for all operating expenses as well as other line items which eventually lead to the net income for the company. Revenue is an extremely important metric when analyzing a company. A company with efficient margins is able to turn revenues into the most net income.
Revenue (Annual) Range, Past 5 Years
22.53M
Minimum
2020
462.18M
Maximum
2023
203.89M
Average
165.42M
Median
Revenue (Annual) Benchmarks
| Amgen Inc | 28.19B |
| Johnson & Johnson | 85.16B |
| Eli Lilly and Co | 34.12B |
| Madrigal Pharmaceuticals Inc | -- |
| Viking Therapeutics Inc | -- |